November 4, 2026 | TickerRoast Markets Analysis
Revvity (NYSE: RVTY) closed up 7.84% at $163.48 on Tuesday, Nov 3, 2026, from $151.60 the session before, according to Yahoo Finance price data. Volume reached about 3.4 million shares. The life sciences and diagnostics company reported third-quarter results before the open and raised its full-year guidance. Data as of the Nov 3, 2026 close.
A Quarter That Ran Ahead of Revvity’s Own Plan
I read Revvity’s third-quarter release, filed with the SEC, and the numbers are tidy rather than spectacular. Reported revenue rose to $729 million from $699 million a year earlier. Because the company has agreed to sell its immunodiagnostics business in China, it also gives pro forma figures that strip that unit out: pro forma revenue grew 7% to $710 million, and pro forma organic growth was also 7%.
Profitability is where the quarter stood out. Adjusted EPS from continuing operations rose to $1.38 from $1.18, and the adjusted operating margin widened to 28.7% from 26.1%. On a pro forma adjusted basis, the margin reached 29.4%, up from 26.0%. GAAP EPS from continuing operations came in at $0.56, compared with $0.41 a year earlier.
Chief executive Prahlad Singh called it an “exceptional third quarter” and said results came in “meaningfully ahead of our expectations.” That phrase matters, because the stock reaction tells me the market had not priced in a quarter running ahead of management’s own plan.
Life Sciences Did the Heavy Lifting
The segment split explains the mood. Life Sciences revenue rose to $380 million from $343 million, with pro forma revenue up 11% and pro forma organic revenue up 9%, and its adjusted operating margin improved to 31.5% from 29.5%. That is the business that sells reagents and instruments to drug developers and research labs, an end market that spent much of the past two years digesting excess inventory and tighter biotech funding.
Diagnostics was steadier. Reported revenue dipped to $349 million from $356 million, largely a reflection of the China unit being sold, while pro forma revenue rose 4% and pro forma organic revenue 5%. The segment’s adjusted operating margin jumped to 29.9% from 25.1%, which suggests the company’s cost program is reaching the income statement.
Why the Stock Moved: Guidance and a Bruised Starting Point
Revvity said it is raising full-year guidance. On its pro forma basis, which excludes China IDX, it now forecasts 2026 revenue of about $2.86 billion, pro forma organic growth of about 5%, and pro forma adjusted EPS of $5.40 to $5.45. Because the company switched to a pro forma basis, I am not comparing that range directly with the guidance it gave in August; the release itself describes the update as a raise.
The starting point also mattered. According to the same Yahoo Finance data, the stock had fallen 5.30% on Oct. 30 and another 3.44% on Nov. 2, so part of Tuesday’s gain simply recovered ground lost in the tech-led sell-off of the prior week. I could not confirm a single analyst consensus figure for the quarter from a source I was able to open, so I am not characterizing the result as a beat of a specific estimate. What I can say from the company’s own words is that management itself expected less.
Context: A Quiet Index Day, a Loud Health Care Name
The broader tape gave little cover either way. According to Yahoo Finance index data, the S&P 500 rose 0.36% to 7,568.92 on Election Day, the Nasdaq Composite gained 0.83% as chip stocks rebounded, and the Dow slipped 0.38%, weighed down by Apple, as StockTitan’s session wrap also noted. Against that backdrop, Revvity was one of the strongest names in the S&P 500; Chartmill listed it among the index’s top gainers alongside Fiserv and Bloom Energy.
What I’ll Be Watching Into Investor Day
Revvity said it will hold an Investor Day on November 13, 2026. I expect that event to matter more than Tuesday’s print, because it is where management is likely to lay out how durable the margin gains are and how it thinks about growth once the China divestment, which the company expects to close by the end of 2027, is behind it. The other thread I will follow is whether the improvement in Life Sciences reflects a broad recovery in lab spending or a few strong product lines. At $163.48, the stock sits not far below its 52-week high of $171.74 and roughly double its 52-week low of $81.22, according to Yahoo Finance, so expectations into that meeting are no longer low.
Sources
- Revvity Announces Financial Results for the Third Quarter of 2026 (Exhibit 99.1, Form 8-K) — Revvity via SEC EDGAR
- Revvity (RVTY) historical prices — Yahoo Finance
- S&P 500 Top Movers: Gainers and Losers on Nov. 3, 2026 — Chartmill
- The Stock Market Today, November 3, 2026 — StockTitan
Market data: Yahoo Finance, close of 2026-11-03. Charts generated by TickerRoast from this data.
Disclaimer: This article is for informational and educational purposes only. It provides general financial and business analysis and does not constitute investment advice, a personal recommendation, a recommendation to buy, sell or hold any security, or an offer to transact in any financial instrument. Information is based on publicly available sources as of November 4, 2026 and market data as of the 2026-11-03 close (Yahoo Finance). Past performance is not a reliable indicator of future results; forecasts are uncertain and actual results may differ materially. Investing in shares involves risk, including the loss of capital. The publisher does not guarantee the accuracy or completeness of the information and accepts no responsibility for investment decisions made on the basis of this article. Readers should consult official company disclosures, conduct their own research and, where appropriate, seek advice from a licensed financial adviser. Any relevant financial interests held by the author or publisher in the securities mentioned are disclosed where applicable. This article was prepared with the assistance of AI tools and is based on the sources listed above.
Anonymous reader poll, just for fun. Not investment advice.
Read next
Get the daily market briefing
The stories that move markets, in your inbox every trading day at 9 a.m. ET. Free, unsubscribe anytime.
